Tag: influenza vacines division
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
Sydney to spotlight the latest in manufacturing at AMW 2024
With the Australian Manufacturing Week (AMW) 2024 fast approaching, Sydney is set to become the epicentre of groundbreaking innovations in the advanced manufacturing sector.Â
